Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States

Journal of Medical Economics

Volumn 15, Issue 3, 2012, Pages 509-520

  Boer, Rob ^a   Lalla, Anjana M ^a   Belozeroff, Vasily ^b  

^a CERNER CORPORATION   (United States)

^b AMGEN INC   (United States)

Author keywords

Chronic kidney disease; End stage renal disease; Pparathyroid hormone; QALY

Indexed keywords

ALUMINUM; BIOLOGICAL MARKER; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; LANTHANUM CARBONATE; MAGNESIUM; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; VITAMIN D;

ARTICLE; CARDIOVASCULAR RISK; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG EFFICACY; FRACTURE; HEALTH CARE COST; HEMODIALYSIS PATIENT; HUMAN; LOW DRUG DOSE; MORTALITY; PARATHYROIDECTOMY; QUALITY OF LIFE; RISK ASSESSMENT; SECONDARY HYPERPARATHYROIDISM; SENSITIVITY ANALYSIS; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; MODELS, ECONOMIC; NAPHTHALENES; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES; YOUNG ADULT;

EID: 84859193508     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.664799     Document Type: Article

References (73)

1. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999;73:S14-S19
2. Owda A, Elhwairis H, Narra S, et al. Secondary hyperparathyroidism in chronic hemodialysis patients: Prevalence and race. Ren Fail 2003;25:595-602
3. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005;16:1788-93
4. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8
5. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18
6. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006;70:1358-66
7. Tentori F, Blayney MJ, Albert J. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-30
8. Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011 Jun;26(6):1948-55
9. NIH. USRDS 2010 Annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Disease, 2010
10. Doan QV, Gleeson M, Kim J, et al. Economic burden of cardiovascular events and fractures among patients with end-stage renal disease. Curr Med Res Opin 2007;23:1561-9
11. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003;42(suppl 3):S1-202
12. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKDMBD). Kidney Int Suppl. 2009;113:S1-130
13. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67:760-71
14. Aparicio M, Combe C, Lafage MH, et al. In advanced renal failure, dietary phosphorus restriction reverses hyperparathyroidism independent of changes in the levels of calcitriol. Nephron 1993;63:122-3
15. Andress DL, Norris KC, Coburn JW, et al. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989;321:274-9
16. Martin KJ, Gonzalez EA, Gellens M, et al. 19-Nor-1-alpha-25- dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9:1427-32
17. Arenas MD, varez-Ude F, Gil MT, et al. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 2007;22:1639-44
18. Arenas MD, Alvarez-Ude F, Torregrosa V, et al. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis. J Nephrol 2007;20:453-61
19. Arenas MD, Alvarez-Ude F, Gil MT, et al. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: Changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Transplant 2006;21:1663-8
20. Al AZ, Gonzalez EA, Martin KJ, et al. Achieving K/DOQI laboratory target values for bone and mineral metabolism: An uphill battle. Am J Nephrol 2004;24:422-6
21. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44(5 Suppl 2):34-8
22. Danese MD, Belozeroff V, Smirnakis K, et al. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008 Sep;3(5):1423-9
23. Messa P, Macá rio F, Yaqoob M, et al. The OPTIMA study: Assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3:36-45
24. Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet HCl and concurrent lowdose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The ACHIEVE study results. Clin J Am Soc Nephrol 2008;3:1718-25
25. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: A randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26:1327-39
26. Floege J, Raggi P, Block GA, et al. Study design and subject baseline characteristics in the ADVANCE Study: Effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2010;25:1916-23
27. Akizawa T, Koshikawa S. Clinical study of cinacalcet in Japan. Ther Apher Dial 2008;12(1 Suppl):S13-S15
28. Akiba T, Akizawa T, Tsukamoto Y, et al. Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 2008;12:117-25
29. Meola M, Petrucci I, Barsotti G. Cinacalcet reduced glandular volume in patients with SHPT [Abstract MP409]. Presented at the XLV ERA-EDTA Congress, May 10-13 2008, Stockholm, Sweden 30. Os I, Bencova V, Banos A, et al. Achievement of KDOQI targets with cinacalcet (mimpara/sensipar) according to length of time on dialyses [Abstract SP394]. Presented at the XLV ERA-EDTA Congress, May 10-13 2008, Stockholm, Sweden 31. Arenas MD, Rebollo P, Alvarez-Ude F, et al. Is cinacalcet a cost-effective treatment in severe secondary hyperparathyroidism in patients on hemodialysis? Nefrologia 2008;28:511-6
30. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800-7
31. Block GA, Martin KJ, de Francisco AL. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. New Engl J Med 2004; 350:1516-25
32. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003;63:248-54
33. Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003;14:575-83
34. Goodman WG, Hladik GA, Turner SA, et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002;13:1017-24
35. Lien YHH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2005;20:1232-7
36. Moe SM, Cunningham J, Bommer J. Long-Term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCL. Nephrol Dial Transplant 2005;20:2186-93
37. Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793-800
38. Lucchi L, Stipo L, Perrone S, et al. Early initiation of cinacalcet (cn) for the treatment of secondary hyperparathyroidism (shpt) in hemodialysis patients [Abstract MP398]. Presented at the XLV ERA-EDTA Congress, May 10-13 2008, Stockholm, Sweden 41. Portoles J, Tato A, Lopez-Sanchez P, et al. Cinacalcet in patients on peritoneal dialysis with moderate to severe hyperparathyroidism resistant to conventional treatment. A one-year, prospective study. Nefrologia 2008; 28:419-24
39. Meier PD, Hertner H, Jungbluth M, et al. KDOQI target achievement is improved with cinacalcet in clinical practice - the Swiss OPTIMIZE survey. [Abstract P54]. Presented at the 41st Annual Meeting Swiss Society of Nephrology. Kursaal Interlaken December 2-4, 2009
40. Spasovski GB. Bone health and vascular calcification relationships in chronic kidney disease. Int Urol Nephrol 2007;39:1209-16
41. Sterrett JR, Strom J, Stummvoll HK, et al. Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 2007;68:10-17
42. Chertow GM, Pupim LB, Block GA, et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and design overview. Clin J Am Soc Nephrol 2007;2:898-905
43. Shireman TI, Almehmi A, Wetmore JB, et al. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Am J Kidney Dis 2010;56:1108-16
44. Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: A systematic review and economic evaluation. Health Technol Assess 2007;11(18)
45. Garside R, Pitt M, Anderson R, et al. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: A UK perspective. Nephrol Dial Transplant 2007;22:1428-36
46. Eandi M, Pradelli L, Iannazzo S, et al. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. Pharmacoeconomics 2010;28):1041-54
47. Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of parathyroidectomy in hemodialysis patients: The USRDS waves 1, 3, and 4 study. Hemodial Int 2007;11:62-71
48. Trespalacios FC, Taylor AJ, Agodoa LY, et al. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis 2003; 41:1267-77
49. Trespalacios FC, Taylor AJ, Agodoa LY, et al. Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int 2002; 62:1799-805
50. Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004; 66:2010-6
51. Gastanaga V, Zhao S, Stuccio-White N, et al. Incidence rates of hospitalization-associated bone fractures in dialysis patients in the United States Renal Data System. Presented at the 22nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 24-27, 2006. Lisbon, Portugal 55. Li S, Chen Y-W, Peng Y, et al. Trends in parathyroidectomy rates in US hemodialysis patients from 1992 to 2007. Am J Kidney Dis. 2011 Apr; 57(4):602-11
52. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive Kidney Diseases, 2009
53. US Department of Health and Human Services. Centers for Medicare and Medicaid Services. Healthcare Common Procedure Coding System. Medicare Part B Drugs Average Price (ASP). 2009. http://www.cms.hhs.gov/ McrPartBDrugAvgSalesPrice/ [Last accessed May 20 2010]
54. 2009 Drug Topics Red Book. Montvale, NJ: Medical Economics, 2009
55. Doan QV, Gleeson M, Kim J, et al. Economic burden of cardiovascular events and fractures among patients with end-stage renal disease. Curr Med Res Opin 2007;23:1561-9
56. Duh Q-Y. Current investigation for primary hyperparathyroidism. Hyperparathyroidism 8th Postgraduate Course in Endocrine Surgery, September 22, 2006, Capsis Beach, Crete 61. HCUPnet. Healthcare Cost and Utilization Project (HCUP). 1993-2008. Rockville, MD: Agency for Healthcare Research and Quality. http://hcupnet. ahrq.gov/. Accessed May 5, 2010
57. US Department of Labor. Bureau of Labor Statistics. http://www.bls.gov/ cpi/home.htm#overview. Accessed February 23, 2009
58. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998;44:215-32
59. Taylor DC, Pandya A, Thompson D, et al. Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. Eur J Health Econ 2009;10:255-65
60. Brazier JE, Green C, Kanis JA. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 2002 Oct;13:(10):768-76
61. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 Suppl 3):S112-9
62. Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol 1998;11:239-45
63. Cases A, Vera M, Lopez Gomez JM. [Cardiovascular risk in patients with chronic renal failure. Patients in renal replacement therapy]. Nefrologia 2002;22(1 Suppl):68-74
64. Suliman ME, Qureshi AR, Barany P, et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000;57:1727-35
65. Marco MP, Craver L, Betriu A. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int 2003;63:S111-4
66. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-87
67. Spiegel DM, Raggi P, Mehta R, et al. Coronary and aortic calcifications in patients new to dialysis. Hemodial Int 2004;8:265-72
68. Block GA, Zaun D, Smits G, et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010 Sep;78(6):578-89
69. Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health economic evaluations: The special case of end-stage renal disease treatment. Med Decis Making 2002;22:417-30
70. Iannazzo S, Pradelli L, Chiroli S. A cost-utility analysis of cinacalcet in secondary hyperparathyroidism (SHPT) in five European countries. Presented at the International Society for Pharmacoeconomics and Outcomes Research 13th Annual European Congress, Toronto, ON, Canada, May 3-7, 2008
71. Amgen. Advisory board to explore the relationship between vascular calcification and clinical and health outcomes in dialysis patients. Amgen data on file. 2010
72. Stevenson M, Lyold Jones M, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005 Jun;9(22):1-160
73. Kim J, Dylan M, Doan Q, et al. Association of elevated serum parathyroid hormone (PTH) and calcium with hip, vertebral, or pelvic fracture in hemodialysis patients [Abstract S026]. Presented at: ERA-EDTA Congress, 15-18 May 2004, Lisbon, Portugal